FindTrial
Sign In

TTo evaluate safety and performance of the Evermine 50-50μm Everolimus-Eluting Coronary Stent System (EES) in the treatment of patients with new native coronary artery lesions.

A retrospective, single-center, study to evaluate safety and performance of the Evermine 50- 50μm Everolimus Eluting Coronary Stent System (EES) in the treatment of patients with de novo coronary artery lesions.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/09/009939
Enrollment
171
Registered
2017-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

Interventions

Intervention1: Evermine 50 - 50 micrometer Everolimus Eluting Coronary Stent System (EES): Everolimus-Eluting Coronary Stent System Control Intervention1: NIL: NIL

Sponsors

Meril Life Sciences Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients who have been treated with Evermine 50 EES. 2. Patients who are contactable, willing to participate will be taken into the study by either signing voluntary informed consent form or by taking telephonic consent of patient.

Exclusion criteria

Exclusion criteria: 1. There are no exclusion criteria for this study.

Design outcomes

Primary

MeasureTime frame
Major Adverse Cardiac Events (MACE), Clinically Driven TLR (CD-TLR), Stent ThrombosisTimepoint: In-hospital, 1 month (±14 days), 6 months (±28days), 12 months (±28 days) and 24 months (±28 days)—

Secondary

MeasureTime frame
1. Ischemic Driven Target Lesion Revascularization(IDTLR) 2. Ischemic Driven Target Vessel Revascularization (IDTVR) 3. Procedural success 4. Device successTimepoint: In-hospital, 1 month (±14 days), 6 months (±28 days), 12 months (±28 days) and 24 months (±28 days)—

Countries

India

Contacts

Public ContactDr Ashok Thakkar

Meril Life Sciences Pvt Ltd

ashok.thakkar@merillife.com9879443584

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 18, 2026